TY - JOUR
T1 - P2Y12 inhibitor monotherapy and dual antiplatelet therapy after percutaneous coronary intervention
T2 - An updated meta-analysis of randomized trials
AU - Jin, Yao
AU - Huang, Hui
AU - Shu, Xinyi
AU - Chen, Shuai
AU - Lu, Lin
AU - Gao, Xiang
AU - Wu, Zhijun
N1 - Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2021/2
Y1 - 2021/2
N2 - Introduction: Long-term dual antiplatelet therapy (DAPT) has substantially reduced the risk of post-percutaneous coronary intervention (PCI) myocardial infarction and stent thrombosis at the expense of major bleeding. We hypothesized that a short-term DAPT followed by extended P2Y12 inhibitor monotherapy might be appropriate for patients with both high ischemic and bleeding risks. Materials and methods: We searched the databases: Pubmed, EMBASE, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov to identify randomized trials assessing the antiplatelet strategies after PCI. The primary safety endpoint was Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding. The efficacy outcome was a composite of all-cause mortality/cardiovascular disease (CVD) death, myocardial infarction, or stroke. A random-effect model was used to calculate the pooled hazard ratios (HRs) with 95% confidence intervals (CIs). Results: We identified 5 randomized trials comparing P2Y12 inhibitor monotherapy with standard DAPT (12 months) (16,057 versus 16,088). P2Y12 inhibitor monotherapy following short-term DAPT (1 to 3 months) significantly reduced the risk of BARC type 3 or 5 bleeding compared to standard DAPT (pooled HR: 0.63, 95%CI: 0.46–0.86). The difference between P2Y12 inhibitor monotherapy and standard DAPT in reducing the composite CVD outcomes was not statistically significant (HR: 0.88, 95%CI: 0.77–1.01). Conclusions: P2Y12 inhibitor monotherapy might be an effective strategy for lowering severe bleeding complications and simultaneously preserving the ischemic benefit in patients receiving PCI.
AB - Introduction: Long-term dual antiplatelet therapy (DAPT) has substantially reduced the risk of post-percutaneous coronary intervention (PCI) myocardial infarction and stent thrombosis at the expense of major bleeding. We hypothesized that a short-term DAPT followed by extended P2Y12 inhibitor monotherapy might be appropriate for patients with both high ischemic and bleeding risks. Materials and methods: We searched the databases: Pubmed, EMBASE, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov to identify randomized trials assessing the antiplatelet strategies after PCI. The primary safety endpoint was Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding. The efficacy outcome was a composite of all-cause mortality/cardiovascular disease (CVD) death, myocardial infarction, or stroke. A random-effect model was used to calculate the pooled hazard ratios (HRs) with 95% confidence intervals (CIs). Results: We identified 5 randomized trials comparing P2Y12 inhibitor monotherapy with standard DAPT (12 months) (16,057 versus 16,088). P2Y12 inhibitor monotherapy following short-term DAPT (1 to 3 months) significantly reduced the risk of BARC type 3 or 5 bleeding compared to standard DAPT (pooled HR: 0.63, 95%CI: 0.46–0.86). The difference between P2Y12 inhibitor monotherapy and standard DAPT in reducing the composite CVD outcomes was not statistically significant (HR: 0.88, 95%CI: 0.77–1.01). Conclusions: P2Y12 inhibitor monotherapy might be an effective strategy for lowering severe bleeding complications and simultaneously preserving the ischemic benefit in patients receiving PCI.
UR - http://www.scopus.com/inward/record.url?scp=85097655517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097655517&partnerID=8YFLogxK
U2 - 10.1016/j.thromres.2020.11.038
DO - 10.1016/j.thromres.2020.11.038
M3 - Article
C2 - 33316640
AN - SCOPUS:85097655517
SN - 0049-3848
VL - 198
SP - 115
EP - 121
JO - Thrombosis Research
JF - Thrombosis Research
ER -